CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tyme Technologies Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tyme Technologies Inc
1 Pluckemin Way - Suite 103
Phone: (212) 461-2315p:212 461-2315 BEDMINSTER, NJ  07921  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 9/16/2022.
This company ceased filing statements with the SEC on 9/30/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Tyme Technologies, Inc. is a biotechnology company. The Company is developing cancer metabolism-based therapies (CMBTs ) that are effective across a broad range of solid tumors and hematologic cancers. It is focused on developing its novel compound, SM-88 and its preclinical pipeline of novel CMBT programs. SM-88 is an oral investigational modified proprietary tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Its therapeutic approach is designed to take advantage of a cancer cells innate metabolic weaknesses to cause cancer cell death.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20223/31/2022YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Douglas A.Michels 65 3/21/2022 10/1/2018
Chief Executive Officer, Director RichardCunningham 51 11/24/2020 11/24/2020
Chief Financial Officer Frank L.Porfido 58 5/13/2021 5/13/2021
7 additional Officers and Directors records available in full report.

Business Names
Business Name
TYME
Tyme, Inc.
TYMI

General Information
Number of Employees: 13 (As of 3/31/2022)
Outstanding Shares: 172,206,894 (As of 8/8/2022)
Shareholders: 170
Stock Exchange: NASD
Federal Tax Id: 453864597
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024